EU disarray: what's happening to the single market?
This article was originally published in Scrip
Last week's ruling by the EU's highest court that a product can be a medical device in one member state and a medicinal product in another qualifies as one of the most disruptive to date. It also comes at an interesting time, as other developments challenge the very principle of the EU single market.
You may also be interested in...
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.